Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 4 and 39 years old.
- You have been diagnosed with dilated cardiomyopathy (your heart's main pumping chamber is enlarged and weak).
- Your heart's pumping strength (ejection fraction) is 45% or less, measured in the last 6 months.
- You have tried standard heart failure medicines for at least 3 months without enough improvement.
- You have not had a heart transplant and are not currently on the waiting list for a transplant.
- You do not have an active infection, cancer (within the last 5 years), or serious kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
This trial tests whether stem cells from donated umbilical cord blood can improve heart function in people with heart failure caused by blocked arteries. You'll receive one or more infusions of these cells through a vein.
This Phase 1 study tests a treatment made from stem cells to grow heart muscle cells (“cardiomyocytes”) for people with long-lasting (chronic) heart weakness after a prior heart attack. It aims to see if the therapy can improve heart function and is safe in carefully selected patients.
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
This study tests a new treatment using donor stem cells injected into the heart during scheduled bypass surgery. The goal is to see if these cells help improve heart function in people with heart failure due to blocked arteries and a weak heart pump.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.